Lysophosphatidic acid enhances antimycobacterial response during in vivo primary Mycobacterium tuberculosis infection

Cell Immunol. 2011;271(1):1-4. doi: 10.1016/j.cellimm.2011.05.014. Epub 2011 Jun 1.

Abstract

Lysophospholipids may play an important protective role during primary infection of Mycobacterium tuberculosis (MTB) by enhancing innate antimycobacterial immune response of both macrophages and alveolar epithelial cells. Here, we show that treatment with lysophosphatidic acid (LPA) of mice aerogenically infected with MTB immediately after infection results in a significant early reduction of pulmonary CFUs and of histopathological damage in comparison with control mice. In contrast, treatment of acute disease does not result in any improvement of both microbiological and histopathological parameters. Altogether, these results show that LPA treatment can exert protective effect if administrated during primary infection, only.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Colony Count, Microbial
  • Female
  • Lung / drug effects*
  • Lung / immunology
  • Lung / microbiology
  • Lysophospholipids / immunology
  • Lysophospholipids / pharmacology*
  • Mice
  • Mice, Inbred BALB C
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / growth & development
  • Mycobacterium tuberculosis / immunology
  • Sphingosine / analogs & derivatives
  • Sphingosine / immunology
  • Sphingosine / pharmacology
  • Time Factors
  • Treatment Outcome
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / immunology
  • Tuberculosis, Pulmonary / pathology

Substances

  • Lysophospholipids
  • sphingosine 1-phosphate
  • Sphingosine
  • lysophosphatidic acid